Cytiva Acquires Vanrx Pharmasystems

Vertex Pharmaceuticals Acquires ViaCyte for $320M

July 11, 2022

Biotechnology

Vertex Pharmaceuticals agreed to acquire clinical-stage cell therapy company ViaCyte for $320 million in cash. The deal gives Vertex additional stem cell lines, IP and GMP manufacturing capabilities intended to accelerate its VX-880 and other cell replacement therapy programs for type 1 diabetes.

Recipharm AB Acquires Vibalogics from Ampersand Capital Partners

February 18, 2022

Biotechnology

Recipharm AB, a global CDMO based in Sweden, has agreed to acquire Vibalogics, a virotherapy-focused CDMO and Ampersand Capital Partners portfolio company. The deal expands Recipharm's capabilities into viral vaccines, viral vectors and oncolytic virus manufacturing while Vibalogics will continue operating from its Boxborough, MA and Cuxhaven, Germany facilities.

Adragos Pharma Acquires Baccinex

February 6, 2025

Pharmaceuticals

Adragos Pharma, a Munich-headquartered CDMO, has acquired Baccinex, a Swiss sterile fill-finish specialist based in Courroux, Jura. The acquisition adds a US FDA- and EU-GMP-certified 6,200 m² facility and over 110 sterile fill-finish experts to Adragos' global manufacturing network, enhancing its clinical and commercial sterile manufacturing capabilities.

Veeva Systems Acquires Crossix Solutions for $430 Million

November 1, 2019

Data & Analytics

Veeva Systems acquired Crossix Solutions for $430 million in a transaction announced September 26, 2019 and closed November 1, 2019. Crossix — a privacy-safe patient data and analytics provider headquartered in New York City — will operate as an independent business unit within Veeva, with Crossix CEO Asaf Evenhaim continuing to lead; certain Crossix employees received long-term equity retention grants valued at about $120 million.

Cambrex Acquires Avista Pharma Solutions

January 2, 2019

Pharmaceuticals

Cambrex Corporation completed the acquisition of Avista Pharma Solutions from Ampersand Capital Partners in a transaction announced November 20, 2018 and completed January 2019 (reported consideration about $252 million). The deal brings Avista’s early‑stage drug development, analytical/testing and finished dosage capabilities (sites in Longmont, CO; Durham, NC; Agawam, MA; and Edinburgh, UK) into Cambrex’s global CDMO network to expand capabilities and cross‑sell services.

Veranex Acquires Fusion Biotec

December 13, 2022

Medical Devices

Veranex has acquired Fusion Biotec, a Southern California design and engineering firm specializing in complex electro-mechanical diagnostic instrumentation and medical devices. The acquisition brings Fusion's 15,000-square-foot facility and 45+ engineering staff into Veranex's Product Design & Engineering capabilities, expanding Veranex's diagnostic/IVD development, software/firmware reuse and Southern California footprint; financial terms were not disclosed.